In-vitro toxicity testing is the scientific analysis of the effects of toxic chemical substances on cultured bacteria or mammalian cells.
Scope of the Report:
This report studies the In-vitro Toxicology Testing market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the In-vitro Toxicology Testing market by product type and applications/end industries.
Significant progress in toxicology science is one of the key trends escalating market growth. Besides this, socio-ethical concerns pertaining to animal tests and high costs associated with conventional animal tests are poised to boost the inclination towards in-vitro toxicology assays.
The global In-vitro Toxicology Testing market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of In-vitro Toxicology Testing.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Quest Diagnostics Inc.
Thermo Fisher Scientific Inc.
Catalent Pharma Solutions
Charles River Laboratories
Eurofins Scientific Inc.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into